<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116382</article-id><article-id pub-id-type="publisher-id">ACM-43088</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_36639034.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  大环内酯类药物对慢性阻塞性肺疾病稳定期抗炎疗效研究进展
  Research Progress of Anti-Inflammatory Effects of Macrolides on Chronic Obstructive Pulmonary Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>曼</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>伟民</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2645</fpage><lpage>2649</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)是一种以持续的呼吸道症状和气流受限为特征，可以预防和治疗的疾病。其具有高发病率、高伤残率、高死亡的特点。COPD的发病机制尚未完全明确，而目前研究表明炎性反应机制仍是疾病进展的核心机制，因此抗炎治疗是关键。大环内酯类药物(Macrolides，简称MA)的抗炎作用逐步得到证实并应用于这类疾病的治疗，本文就MA的生物学特性及其在慢性阻塞性肺疾病稳定期中的疗效做一综述。
   Chronic obstructive pulmonary disease (COPD) is a disease characterized by persistent respiratory symptoms and airflow limitation, which can be prevented and treated. It has the characteristics of high morbidity, disability, and death. The pathogenesis of COPD has not yet been fully clarified, and current studies have shown that the inflammatory response mechanism is still the core mechanism of disease progression, so anti-inflammatory therapy is the key. The anti-inflammatory effects of macrolides (Macrolides abbreviated as MA) have been gradually confirmed and applied to the treatment of such diseases. This article reviews the biological characteristics of MA and its efficacy in the stable phase of chronic obstructive pulmonary disease.
 
</p></abstract><kwd-group><kwd>大环内酯类药物，慢性阻塞性肺疾病，抗炎治疗, Macrolides</kwd><kwd> Chronic Obstructive Pulmonary Disease</kwd><kwd> Anti-Inflammatory Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)是一种以持续的呼吸道症状和气流受限为特征，可以预防和治疗的疾病。其具有高发病率、高伤残率、高死亡的特点。COPD的发病机制尚未完全明确，而目前研究表明炎性反应机制仍是疾病进展的核心机制，因此抗炎治疗是关键。大环内酯类药物(Macrolides，简称MA)的抗炎作用逐步得到证实并应用于这类疾病的治疗，本文就MA的生物学特性及其在慢性阻塞性肺疾病稳定期中的疗效做一综述。</p></sec><sec id="s2"><title>关键词</title><p>大环内酯类药物，慢性阻塞性肺疾病，抗炎治疗</p></sec><sec id="s3"><title>Research Progress of Anti-Inflammatory Effects of Macrolides on Chronic Obstructive Pulmonary Disease</title><p>Man Zhang, Weimin Sun</p><p>Yan’an University Affiliated Hospital, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/24-1572311x4_hanspub.png" /></p><p>Received: May 10<sup>th</sup>, 2021; accepted: May 29<sup>th</sup>, 2021; published: Jun. 11<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/24-1572311x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Chronic obstructive pulmonary disease (COPD) is a disease characterized by persistent respiratory symptoms and airflow limitation, which can be prevented and treated. It has the characteristics of high morbidity, disability, and death. The pathogenesis of COPD has not yet been fully clarified, and current studies have shown that the inflammatory response mechanism is still the core mechanism of disease progression, so anti-inflammatory therapy is the key. The anti-inflammatory effects of macrolides (Macrolides abbreviated as MA) have been gradually confirmed and applied to the treatment of such diseases. This article reviews the biological characteristics of MA and its efficacy in the stable phase of chronic obstructive pulmonary disease.</p><p>Keywords:Macrolides, Chronic Obstructive Pulmonary Disease, Anti-Inflammatory Treatment</p><disp-formula id="hanspub.43088-formula25"><graphic xlink:href="//html.hanspub.org/file/24-1572311x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/24-1572311x7_hanspub.png" /> <img src="//html.hanspub.org/file/24-1572311x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)以持续的呼吸道症状和气流受限为特征，是可以预防和治疗的一种气道疾病。世界卫生组织关于病死率及死因的预测最新数据显示，随着发展中国家吸烟率的升高和高收入国家的人口老龄化加剧，慢阻肺的患病率在未来40年将继续上升，预测至2060年死于慢阻肺及其相关疾患者数超过每年540万人 [<xref ref-type="bibr" rid="hanspub.43088-ref1">1</xref>]。COPD是长期累积的有毒气体和颗粒暴露以及基因、气道高反应和幼年时肺发育不良等多种宿主因素复杂相互作用的结果 [<xref ref-type="bibr" rid="hanspub.43088-ref2">2</xref>]。多种炎性细胞如中性粒细胞、巨噬细胞、T淋巴细胞、嗜酸性粒细胞等参与了COPD的发病过程，蛋白酶增多或抗蛋白酶不足及其活性下降亦可导致COPD。氧化应激会损伤生物大分子，导致细胞功能障碍或细胞死亡，还可破坏细胞外基质，引起蛋白酶及抗蛋白酶失衡，促进炎症反应，最终导致COPD发生 [<xref ref-type="bibr" rid="hanspub.43088-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.43088-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.43088-ref5">5</xref>]。根据GOLD指南，炎性反应机制仍是疾病进展的核心环节，将引起肺结构性变化，小气道狭窄和肺实质破坏，最终导致肺泡与小气道的附着受到破坏，降低肺弹性回缩力。对于COPD患者稳定期的治疗是以舒张支气管以改善气道受限，抑制慢性炎症、延缓气道重塑为主，而目前主要的抗炎药物是糖皮质激素。</p><p>近年来，国内外多项研究证实，对于COPD患者，大环内酯类药物(Macrolides，简称MA)小剂量长期应用能够有效抑制其呼吸道粘膜的分泌，促使气道通畅，改善咳痰、喘息、呼吸困难、发绀等临床症状和体征，改善患者的肺功能，促进血气分析指标恢复正常，同时还可减少COPD的急性发作的频率，从而明显改善患者的生活质量 [<xref ref-type="bibr" rid="hanspub.43088-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.43088-ref7">7</xref>]。本文就大环内酯类药的生物学特性及其在慢性阻塞性肺疾病稳定期的疗效做一综述，为其更加合理有效地应用于稳定期慢性阻塞性肺疾病的抗炎治疗提供参考。</p></sec><sec id="s6"><title>2. MA的生物学特性及分类</title><p>MA是一类具有12-16碳内酯环共同化学结构的药物，其结构由大内酯环与糖通过氧桥连接而成，难溶于水，药物代谢动力学特征是组织浓度高于血液浓度，所以是组织高浓度分布的抗生素。它的主要作用是快速抑制蛋白质合成，对需氧革兰阳性菌、部分阴性菌及非典型致病菌具有抗菌作用，同时还具有抗炎、免疫调节、抗纤维化、抑制黏液分泌、细胞保护、细胞穿透、抑制肿瘤血管生成，从而发挥抗肿瘤、化学黏连及促胃肠动力等作用 [<xref ref-type="bibr" rid="hanspub.43088-ref8">8</xref>]。按化学结构MA可分为14元环、15元环和16元环三类，14、15元环类不仅具有抗菌作用，同时具有抗炎和免疫调节作用，尤其是抑制中性粒细胞及巨噬细胞的功能与活性，而16环交酯类并未见突出的抑制炎症反应及免疫调节的功效 [<xref ref-type="bibr" rid="hanspub.43088-ref9">9</xref>]。按其来源和药动学规律，MA可分为三代。第一代为天然品种，有14元环的红霉素(EM)，16元环的吉他霉素和交沙霉素等；第二代为半合成品种，是对EM的大环内酯环加以化学改造形成的一系列衍生物，如克拉霉素(CAM)、罗红霉素(RXM)等，15元环的阿奇霉素(AZM)，16元环的罗他霉素和醋酸麦迪霉素等 [<xref ref-type="bibr" rid="hanspub.43088-ref8">8</xref>]。</p></sec><sec id="s7"><title>3. MA在COPD中的抗炎机制及疗效进展</title><p>COPD不仅是气道、肺实质、肺血管的慢性局性炎症，也是各种炎性细胞参与的全身炎症反应性疾病。在其发病过程中，主要的炎性细胞包括中性粒细胞、巨噬细胞、树突状细胞、CD4+T淋巴细胞、CD8+T淋巴细胞、嗜酸性粒细胞等，故抗炎治疗是核心与重点。目前临床上应用最广的抗炎药物当属糖皮质激素，但随着对COPD炎症机制研究的深入，在对气道慢性炎症持续的控制方面，有研究发现，大环内酯类药物不仅具有抗菌效应，还能发挥一定的免疫调节作用 [<xref ref-type="bibr" rid="hanspub.43088-ref10">10</xref>]。既往观察发现，长期接受小剂量AZM治疗的COPD患者发生急性加重的次数较安慰剂组明显降低，提高了患者生活质量，而经证实大环内酯类药物能通过调控细胞因子及趋化因子等方式减少气道内中性粒细胞及巨噬细胞的聚集，且EM亦能有效降低肺泡灌洗液中的中性粒细胞、巨噬细胞及淋巴细胞数量，正因如此，在GOLD的最新指南的治疗建议中增加了大环内酯类药物的治疗 [<xref ref-type="bibr" rid="hanspub.43088-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.43088-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.43088-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.43088-ref14">14</xref>]。但目前大环内酯类药物抑制炎症的治疗靶点及确切抗炎机制尚不清晰。</p><p>有大量研究表明，MA可有效抑制炎性介质的产生，如INF-α、IL-6、IL-8、IL-12等，进而减少气道黏液的分泌，减轻气道的损害程度，改善肺功能并提高患者的生活质量。2013年何杰等 [<xref ref-type="bibr" rid="hanspub.43088-ref15">15</xref>] 的一项meta分析表明，长期低剂量应用MA不但能够改善患者的生活质量、运动耐力和肺功能，还可以明显降低患者COPD急性加重期的次数，从而降低患者的住院率。针对大环内酯类药物对COPD治疗显效的机制，目前认为其在抑制慢性炎症的同时不能排除抗菌作用的影响。Seemungal等 [<xref ref-type="bibr" rid="hanspub.43088-ref16">16</xref>] 应用EM (250 mg，每日2次)治疗109例COPD患者12个月，结果发现EM组中COPD急性加重次数较对照组明显减少，但对于第一秒用力呼吸容积(FEV1)及血、痰中的炎症因子IL-6、IL-8及C反应蛋白(CRP)没有影响。Basyigit等 [<xref ref-type="bibr" rid="hanspub.43088-ref17">17</xref>] 以单中心、双盲及安慰剂对照用CAM治疗轻度/中度COPD患者急性加重期，疗程14天，结果CAM治疗组治疗前、后血清及诱导痰中细胞总数、IL-8及TNF-α水平显著下降，肺功能测定与动脉血气分析结果显著改善，安慰剂组治疗前、后各项结果未见明显改善；结果表明CAM通过降低血清与诱导痰细胞数、IL-8和TNF-α等抗炎作用使气道炎症改善，从而改善各项血清学检测指标及肺功能。黄招兰等 [<xref ref-type="bibr" rid="hanspub.43088-ref18">18</xref>] 研究结果显示AZM小剂量疗法可以明显降低慢阻肺稳定期老年患者气道炎症反应，其主要机制是抑制多种炎性介质INF-α、IL-8和CRP等激活炎症细胞，从而减轻COPD炎症反应对气道的炎症损伤。王敏等 [<xref ref-type="bibr" rid="hanspub.43088-ref19">19</xref>] 研究结果表明AZM能通过降低COPD稳定期静脉血中IL-17水平，致使促炎性因子如IL-6、IL-8的释放减少，进而减弱炎性细胞在气道内趋化，明显降低了过度的炎症反应，并能改善临床症状。在2019年魏洋亿 [<xref ref-type="bibr" rid="hanspub.43088-ref20">20</xref>] 的临床荟萃分析中，最终纳入标准的文献有10篇，这些文献中纳入的病例中大多数患者有中度至重度COPD，在进入研究之前经历过急性加重期。治疗组848例患者随机分为大环内酯类药物治疗组(CAM治疗1个，EM4个，AZM5个)，对照组854例。3篇文献的治疗疗程为3个月，2篇文献的治疗疗程为6个月，5篇文献的治疗疗程为12个月。结果显示，长期大环内酯类药物能有效预防COPD患者急性发作的发生(RR = 0.67, 95% CI: 0.55~0.83, p &lt; 0.05)。虽然大环内酯类药物抗炎治疗靶点暂不明确，但大量研究证实，MA可通过减少炎性细胞的生成、抑制炎症细胞介导反应、促进炎症细胞提前凋亡、减轻下气道黏液分泌量等机制，有效减轻COPD患者炎症反应，进而减轻气道损伤，改善肺功能及临床症状并有助于提高生活质量，其用于COPD的抗炎治疗值得深入研究。</p></sec><sec id="s8"><title>4. 结论</title><p>综上所述，14、15元环的大环内酯类抗生素对COPD患者的抗炎作用是肯定的，小剂量长期应用可明显改善COPD患者的症状，降低急性加重次数，提高患者生活质量，然而现有研究尚未明确规定该类药物使用剂量及疗程问题，以及长期使用该药物对患者的副作用评价，故还需更多相关临床研究用于评价其疗效及安全性。</p></sec><sec id="s9"><title>文章引用</title><p>张 曼,孙伟民. 大环内酯类药物对慢性阻塞性肺疾病稳定期抗炎疗效研究进展Research Progress of Anti-Inflammatory Effects of Macrolides on Chronic Obstructive Pulmonary Disease[J]. 临床医学进展, 2021, 11(06): 2645-2649. https://doi.org/10.12677/ACM.2021.116382</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43088-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2021 REPORT). &lt;br&gt;https://goldcopd.org/gold reports/</mixed-citation></ref><ref id="hanspub.43088-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lange, P., Celli, B., Agusti, A., et al. (2015) Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. The New England Journal of Medicine, 373, 111-122. &lt;br&gt;https://doi.org/10.1056/NEJMoa1411532</mixed-citation></ref><ref id="hanspub.43088-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Robbins, C.S., Franco, F., Mouded, M., et al. (2008) Cigarette Smoke Exposure Impairs Dendritic Cell Maturation and T Cell Proliferation in Thoracic Lymph Nodes of Mice. The Journal of Immunology, 180, 6623-6628.  
&lt;br&gt;https://doi.org/10.4049/jimmunol.180.10.6623</mixed-citation></ref><ref id="hanspub.43088-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Lams, B.E., Sousa, A.R., Rees, P.J., et al. (1998) Immunopathology of the Small Airway Submucosa in Smokers with and without Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 158, 1518-1523. &lt;br&gt;https://doi.org/10.1164/ajrccm.158.5.9802121</mixed-citation></ref><ref id="hanspub.43088-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Feghali-Bostwick, C.A., Gadgil, A.S., Otterbein, L.E., et al. (2008) Autoantibodies in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 177, 156-163.  
&lt;br&gt;https://doi.org/10.1164/rccm.200701-014OC</mixed-citation></ref><ref id="hanspub.43088-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Albert, R.K., Connett, J., Bailey, W.C., et al. (2011) Azithromycin for Prevention of Exacerbations of COPD. The New England Journal of Medicine, 365, 689-698. &lt;br&gt;https://doi.org/10.1056/NEJMoa1104623</mixed-citation></ref><ref id="hanspub.43088-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">曾瑜, 林健濂, 黎俏琴. 长期小剂量罗红霉素对稳定期慢性阻塞性肺疾病的临床价值分析[J]. 中国实用医药, 2013(33): 165-166.</mixed-citation></ref><ref id="hanspub.43088-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">郭韶梅, 钟小宁. 大环内酯类药物在慢性阻塞性肺疾病气道及肺部炎症中的作用[J]. 国外医学(呼吸系统分册), 2005, 25(11): 813-815.</mixed-citation></ref><ref id="hanspub.43088-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">邱诗林, 钟小宁. 大环内酯类药物治疗慢性阻塞性肺疾病现状及启示[J]. 中国实用内科杂志, 2015, 35(5): 395-398.</mixed-citation></ref><ref id="hanspub.43088-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tillack, K., Breiden, P., Martin, R., et al. (2012) T Lymphocyte Priming by Neutrophil Extracellular Traps Links Innate and Adaptive Immune Responses. The Journal of Immunology, 188, 3150-3159.  
&lt;br&gt;https://doi.org/10.4049/jimmunol.1103414</mixed-citation></ref><ref id="hanspub.43088-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lapponi, M.J., Carestia, A., Landoni, V.I., et al. (2013) Regulation of Neutrophil Extracellular Trap Formation by Antiinflammatory Drugs. Journal of Pharmacology and Experimental Therapeutics, 345, 430-437.  
&lt;br&gt;https://doi.org/10.1124/jpet.112.202879</mixed-citation></ref><ref id="hanspub.43088-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">He, Z.Y., Ou, L.M., Zhang, J.Q., et al. (2010) Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease. Respiration, 80, 445-452.  
&lt;br&gt;https://doi.org/10.1159/000321374</mixed-citation></ref><ref id="hanspub.43088-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kanoh, S. and Rubin, B.K. (2010) Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications. Clinical Microbiology Reviews, 23, 590-615. &lt;br&gt;https://doi.org/10.1128/CMR.00078-09</mixed-citation></ref><ref id="hanspub.43088-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Y., Tan, X., Kuang, W., et al. (2012) Erythromycin Ameliorates Cigarette Smoke Induced Emphysema and Inflammation in Rats. Translational Research, 159, 464-472. &lt;br&gt;https://doi.org/10.1016/j.trsl.2011.09.007</mixed-citation></ref><ref id="hanspub.43088-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">何杰, 杨济桥, 童翔, 付晓巍, 李小燕, 范红. 大环内酯类抗生素对COPD患者急性加重频率影响的系统评价[J]. 中国呼吸与危重监护杂志, 2013, 12(1): 12-18.</mixed-citation></ref><ref id="hanspub.43088-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Seemungal, T.A., Wilkinson, T.M., Hurst, J.R., et al. (2008) Long-Term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations. American Journal of Respiratory and Critical Care Medicine, 178, 1139-1147. &lt;br&gt;https://doi.org/10.1164/rccm.200801-145OC</mixed-citation></ref><ref id="hanspub.43088-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Basyigit, I., Yildiz, F., Ozkara, S.K., et al. (2004) The Effect of Clarithromycin on Inflammatory Markers in Chronic Obstructive Pulmonary Disease: Preliminary Data. Annals of Pharmacotherapy, 38, 1400-1405.  
&lt;br&gt;https://doi.org/10.1345/aph.1D634</mixed-citation></ref><ref id="hanspub.43088-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">黄招兰, 杨贵丽, 王惠玲, 吴淑芳, 王燕华. 小剂量阿奇霉素治疗对慢性阻塞性肺疾病稳定期老年患者肺功能和炎症因子的影响[J]. 中国老年学杂志, 2016(1): 135-136.</mixed-citation></ref><ref id="hanspub.43088-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">王敏, 尹晓玲, 高玉林, 李晶. 长期小剂量阿奇霉素对慢性阻塞性肺疾病稳定期患者的免疫调节作用研究[J]. 甘肃科技, 2016, 32(12): 112-114.</mixed-citation></ref><ref id="hanspub.43088-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">魏洋亿. 大环内酯类药物预防慢性阻塞性肺疾病急性发作的Meta分析[J]. 国外医药(抗生素分册), 2019, 40(2): 155-165.</mixed-citation></ref></ref-list></back></article>